This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, S. D.
Right arrow Articles by Traczewski, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, S. D.
Right arrow Articles by Traczewski, M. M.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, July 2007, p. 2173-2179, Vol. 45, No. 7
0095-1137/07/$08.00+0     doi:10.1128/JCM.02351-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Comparative In Vitro Antimicrobial Activity of Tigecycline, a New Glycylcycline Compound, in Freshly Prepared Medium and Quality Control{triangledown}

Steven D. Brown* and Maria M. Traczewski

The Clinical Microbiology Institute, 9725 SW Commerce Circle, Wilsonville, Oregon 97070

Received 20 November 2006/ Returned for modification 5 February 2007/ Accepted 1 May 2007

The in vitro spectra of activity of tigecycline and tetracycline were determined for 2,490 bacterial isolates representing 50 different species or phenotypic groups. All isolates were tested simultaneously by broth microdilution using freshly prepared Mueller-Hinton broth and by disk diffusion. Portions of these data were submitted to the Food and Drug Administration (FDA) in support of the sponsor's application for new drug approval. In a separate study, MIC and disk diffusion quality control ranges were determined. The tigecycline MICs at which 50%/90% of bacteria were inhibited were (in µg/ml) as follows: for Streptococcus spp., 0.06/0.12; for Moraxella catarrhalis, 0.06/0.12; for Staphylococcus spp., 0.12/0.25; for Enterococcus spp., 0.12/0.25; for Listeria monocytogenes, 0.12/0.12; for Neisseria meningitidis, 0.12/0.25; for Haemophilus spp., 0.25/0.5; for Enterobacteriaceae, 0.05/2.0; for non-Enterobacteriaceae, 0.5/8.0. Tigecycline was consistently more potent than tetracycline against all species studied. The data from this study confirm the FDA-approved MIC and disk diffusion breakpoints for tigecycline for Streptococcus spp. other than Streptococcus pneumoniae, enterococci, and Enterobacteriaceae. Provisional breakpoints for Haemophilus spp. and S. pneumoniae are proposed based on the data from this study. The following MIC and/or disk diffusion quality control ranges are proposed: Staphylococcus aureus ATCC 29213, 0.03 to 0.25 µg/ml; S. aureus ATCC 25923, 20 to 25 mm; Escherichia coli ATCC 25922, 0.03 to 0.25 µg/ml and 20 to 27 mm; Pseudomonas aeruginosa ATCC 27853, 9 to 13 mm, Enterococcus faecalis ATCC 29212, 0.03 to 0.12 µg/ml; S. pneumoniae ATCC 49619, 0.015 to 0.12 µg/ml and 23 to 29 mm; Haemophilus influenzae ATCC 49247, 0.06 to 0.5 µg/ml and 23 to 31 mm; and Neisseria gonorrhoeae ATCC 49226, 30 to 40 mm.

* Corresponding author. Mailing address: The Clinical Microbiology Institute, 9725 SW Commerce Circle, Wilsonville, OR 97070. Phone: (503) 682-3232. Fax: (503) 682-2065. E-mail: sbrown{at}clinmicroinst.com

{triangledown} Published ahead of print on 9 May 2007.

Journal of Clinical Microbiology, July 2007, p. 2173-2179, Vol. 45, No. 7
0095-1137/07/$08.00+0     doi:10.1128/JCM.02351-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Capoor, M. R., Nair, D., Posti, J., Singhal, S., Deb, M., Aggarwal, P., Pillai, P. (2009). Minimum inhibitory concentration of carbapenems and tigecycline against Salmonella spp.. J Med Microbiol 58: 337-341 [Abstract] [Full Text]  
  • Kelesidis, T., Karageorgopoulos, D. E., Kelesidis, I., Falagas, M. E. (2008). Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 62: 895-904 [Abstract] [Full Text]  
  • Salas, C., Calvo, J., Martinez-Martinez, L. (2008). Activity of Tigecycline against Coryneform Bacteria of Clinical Interest and Listeria monocytogenes. Antimicrob. Agents Chemother. 52: 1503-1505 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»